Advaxis (NASDAQ:ADXS – Get Rating) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.
Earnings & Valuation
This table compares Advaxis and Milestone Pharmaceuticals' revenue, earnings per share and valuation.
Get Advaxis alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Advaxis | $3.24 million | 2.07 | -$17.86 million | ($6.70) | -0.55 |
| Milestone Pharmaceuticals | $15.00 million | 15.51 | -$42.85 million | ($1.46) | -5.31 |
Advaxis has higher earnings, but lower revenue than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Advaxis and Milestone Pharmaceuticals, as reported by MarketBeat.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Advaxis | 0 | 0 | 0 | 0 | N/A |
| Milestone Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
Milestone Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 29.03%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Advaxis.
Profitability
This table compares Advaxis and Milestone Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Advaxis | N/A | -39.23% | -33.85% |
| Milestone Pharmaceuticals | N/A | -57.80% | -54.81% |
Institutional and Insider Ownership
0.1% of Advaxis shares are owned by institutional investors. Comparatively, 67.7% of Milestone Pharmaceuticals shares are owned by institutional investors. 0.3% of Advaxis shares are owned by insiders. Comparatively, 5.6% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Advaxis has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500.
Summary
Milestone Pharmaceuticals beats Advaxis on 8 of the 12 factors compared between the two stocks.
About Advaxis
(Get Rating)
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
About Milestone Pharmaceuticals
(Get Rating)
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.